MOTS-c vs NAD+ vs SS-31 vs Humanin
Four mitochondrial stories. Four different evidence trails.
A cofactor, a membrane target and two signaling peptides do not tell the same story.
THE 30-SECOND ANSWER
What actually
sets them apart?
These are not four versions of the same mitochondrial treatment. NAD+ participates in redox chemistry and enzyme reactions; MOTS-c is investigated as a metabolic stress signal; SS-31 binds cardiolipin; Humanin has experimental cell-survival actions. Their human evidence is also unequal and disease-specific. None of the comparisons reviewed here establishes a four-way winner for healthy-person energy, fat loss, hypertrophy or longevity, and different mechanisms do not prove a beneficial stack.
- A mitochondrial connection does not make the molecules interchangeable.
- Endogenous levels, administered treatment and modified analogs are separate evidence categories.
- Disease-specific clinical evidence can be important without establishing healthy-person enhancement.
MOTS-c
Mitochondrial open reading frame of the 12S rRNA-c
Research emphasizes metabolic stress responses. Human exercise-associated levels are not evidence that administering the peptide improves performance.
NAD+
Oxidized nicotinamide adenine dinucleotide
Not a peptide. Direct NAD+ administration is distinct from giving its precursors NR or NMN.
SS-31
Elamipretide
Targets mitochondrial membrane biology. Forzinity has a specific US accelerated approval for Barth syndrome—not general rejuvenation.
Humanin
Humanin; distinct from modified analogs such as HNG
Studied for cytoprotective mechanisms. Endogenous biomarker observations and administered-treatment outcomes must remain separate.
INSIDE THE MECHANISM
Follow the signal.
Then test the story.
Explore four parallel targets. These are distinct research tracks—not a sequence, a combination protocol or a potency ranking.
Conceptual target symbols only. No arrows connect the compounds: combined benefit has not been established.
METABOLIC STRESS · AMPK-RELATED SIGNALING
MOTS-c
Cell and mouse experiments connect MOTS-c with folate/purine metabolism, AMPK-related responses and metabolic homeostasis. A separate experiment showed stress-dependent movement into the nucleus and effects on gene regulation. These are mechanistic leads, not a measured human fat-loss effect.
COFACTOR · REDOX AND ENZYME REACTIONS
NAD+
NAD+ and NADH participate in electron-transfer chemistry. NAD+ is also consumed by enzymes involved in cellular regulation and repair. Adding NAD+ to blood does not automatically establish delivery to the relevant intracellular pool, nor prove that ATP production or perceived energy improves.
MEMBRANE · CARDIOLIPIN BINDING
SS-31
Elamipretide is a mitochondrial cardiolipin binder. This is a membrane-focused pharmacological approach, not replenishment of NAD+ and not the same signal as an endogenous mitochondrial-derived peptide. Its clinical question must be tied to the disease and functional endpoint actually studied.
CELL SURVIVAL · EXPERIMENTAL BAX INTERACTION
Humanin
In cellular and isolated-mitochondria experiments, Humanin interacted with Bax and inhibited steps in apoptotic signaling. That provides a plausible cytoprotective research pathway. It does not demonstrate that injecting Humanin prevents neurodegeneration or extends human life.
THE EXPERIMENTS BEHIND THE EXPLANATION
What was
actually measured?
Check the population, comparator and endpoint. A direct randomized comparison answers a different question from results collected in separate studies.
MOTS-c and exercise
The 2021 performance paper administered MOTS-c to mice; its human component measured endogenous peptide after exercise in ten men.
The finding
Mouse performance findings and exercise-associated human levels supported further research.
The boundary
The human participants were not given MOTS-c. The registered phase II trial currently has no posted results.
Direct NAD+ has more than biomarker research
180 adults with ischemic-cardiomyopathy heart failure received seven days of IV NAD+ or placebo alongside standard care.
The finding
One-month ejection-fraction improvement favored NAD+. Six-month clinical-event and heart-failure hospitalization differences were not statistically significant.
The boundary
Single-center, disease-specific study; not a trial of wellness, longevity, fat loss or gym performance.
A meaningful null result for SS-31
MMPOWER-3: 218 people with primary mitochondrial myopathy; twenty-four weeks of subcutaneous elamipretide or placebo.
The finding
The co-primary walking-distance and fatigue endpoints were not met.
The boundary
This condition is not interchangeable with Barth syndrome, and neither population represents healthy enhancement.
Humanin after training
Twelve-week resistance-training research in men with impaired glucose regulation measured their own Humanin.
The finding
Skeletal-muscle Humanin increased; circulating Humanin did not change.
The boundary
The intervention was exercise, not Humanin administration. A biomarker response does not demonstrate a treatment effect.
The target is not the outcome
| Compound / research target | What the evidence can support | What it does not yet establish here |
|---|---|---|
| MOTS-c · metabolic stress signaling | Preclinical intervention effects; human endogenous physiology; a registered human trial | Established administered-peptide fat-loss or exercise efficacy |
| NAD+ · redox cofactor / enzyme substrate | Human exposure data and a disease-specific randomized cardiac signal | General rejuvenation or equivalence to NR/NMN |
| SS-31 · cardiolipin | Specific Barth-syndrome accelerated approval; mixed clinical results by disease | A universal mitochondrial-energy upgrade |
| Humanin · cell-survival pathways | Preclinical mechanisms and endogenous human associations | Proven injected-Humanin clinical benefits |
Four parallel research tracks, not a sequence or a potency ranking. Registry status and the FDA indication were checked October 17, 2026 UTC. Source: mots-trialSource: nad-heartSource: fda-forzinitySource: humanin-baxSource: humanin-registry
REPUTATION MEETS RESEARCH
The claim.
The missing context.
Anecdotes can generate useful questions. They cannot isolate the molecule’s effect, establish a response rate or supply a reliable ranking.
“They all boost mitochondria, so they should be interchangeable.”
That label hides the target. A cofactor pool, a membrane lipid and a signaling response are different biological features. An intervention can affect one without reproducing the effect of another. The shared organelle is a theme, not a mechanism of equivalence.
“More of the peptide after exercise means injections reproduce exercise.”
An exercise-associated biomarker may participate in adaptation, respond to it, or track other changes. Administering it is a new experiment. To claim an exercise-like benefit, researchers must test the intervention itself and measure the relevant function.
“Four complementary mechanisms prove synergy.”
Complementarity is a hypothesis. Demonstrating synergy requires a design capable of distinguishing the combination from its components and expected additive effects. No such four-way human trial was identified here; more targets could mean no added benefit or additional risk.
Start with the bottleneck, not the word “energy”
Energy can mean several things in a testimonial: less sleepiness, more motivation, reduced fatigue, a longer run or better recovery. Those are not interchangeable outcomes. A molecule that changes a laboratory marker has not automatically answered any of them. The first useful question is which process is thought to be limiting function, and how an experiment would test that explanation.
This makes the comparison more concrete. Rather than asking which is the best mitochondrial compound, ask whether a specific intervention changes a specific outcome in a relevant population. That framing can accommodate genuinely promising biology without making every mitochondrial target sound like a universal battery replacement.
Source: mmpowerSource: nad-heartMOTS-c: the exercise story has two distinct halves
The mouse intervention results are interesting because they move beyond an association: researchers administered the peptide and measured performance. The human exercise measurements answer a different question about endogenous physiology. Combining the two into “MOTS-c improved endurance in humans” would remove the very distinction that makes the experiment interpretable.
Human administration is now represented by a registered phase II MOTS-c study, NCT07505745. At this check it was recruiting, with an estimated enrollment of 120 and no posted results. That is an important development milestone, not evidence of efficacy. It is also distinct from research involving the analog CB4211.
Source: mots-exerciseSource: mots-trialNAD+: delivery is part of the biological claim
A 2019 pilot examined plasma and urine metabolites during a six-hour IV NAD+ infusion in eleven men, with eight receiving NAD+ and three saline. It characterized exposure and metabolism, not improved muscle performance or mitochondrial delivery. Such work helps establish what happens after administration but cannot substitute for a clinical-outcome trial.
The later randomized heart-failure study is therefore worth recognizing rather than saying direct NAD+ has no human clinical research. Its positive ejection-fraction signal remains limited to the tested context, with no statistically significant clinical-event reduction. Studies of oral precursors, other routes or different preparations should be assessed separately rather than merged into one NAD evidence claim.
Source: nad-pilotSource: nad-heartSS-31: a real approval with a narrow meaning
FDA approved Forzinity on September 19, 2025, through accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. The supporting strength increases occurred during an open-label extension; the initial randomized portion did not show superiority on the primary walking and fatigue endpoints. Continued confirmation of clinical benefit matters.
This is neither a reason to dismiss the treatment nor permission to generalize its indication. The larger MMPOWER-3 null result illustrates that even within mitochondrial diseases, a target-based rationale does not guarantee the same clinical outcome. Diagnosis, trial design and endpoint remain essential parts of the story.
Source: fda-forzinitySource: mmpowerHumanin: cell protection is a research lead, not an anti-aging outcome
The Bax experiment gives Humanin a specific mechanistic story: interference with an apoptotic pathway under experimental conditions. That is more informative than a vague claim that it heals mitochondria. But preventing a laboratory cell-death response does not establish prevention of a complex human disease.
A focused review of published evidence and registry records did not identify an efficacy trial administering Humanin to people. Human registry studies instead included endogenous measurements and interventions such as exercise or anesthesia. Native Humanin and modified analogs also need separate identities; an impressive animal result with an analog should not silently become a claim about every Humanin preparation.
Source: humanin-baxSource: humanin-registryWhat would make the comparison decisive?
A useful healthy-person trial would define the intended benefit before enrollment, specify the exact compound and formulation, and measure relevant exposure. It would randomize against an appropriate control and use outcomes such as validated fatigue scores, reproducible performance testing or directly measured body composition—not only a molecular marker.
For a combination, the components need their own comparison groups. Otherwise an apparent improvement cannot establish which component contributed, whether the combination added anything, or whether the result exceeds a simpler explanation. This is an editorial standard for interpreting evidence, not a proposal for personal experimentation.
Source: mmpowerSource: mots-trialTAKE THIS WITH YOU
The useful comparison.
The most useful comparison is target plus evidence: metabolic signaling for MOTS-c, cofactor chemistry for NAD+, membrane binding for SS-31 and experimental cytoprotection for Humanin. These are intriguing but distinct research programs. The next leap—from mechanism to a meaningful human benefit—must be demonstrated for each, and separately for any combination.
Explore the study summaries →CHECK THE WORK
Sources & reading notes
Focused editorial review, not a systematic review or treatment guide. Access and study type are stated below. Numerical details are limited to the material reviewed.
- Lee et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. 2015. PMID 25738459. ↗Cell and mouse intervention research · primary mechanistic findings reviewed
- Kim et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. 2018. PMID 29983246. ↗Preclinical cellular mechanism · no human clinical efficacy inferred
- Reynolds et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. 2021. PMID 33473109. ↗Primary abstract and experimental description reviewed · mouse treatment versus endogenous human exercise measurements distinguished
- ClinicalTrials.gov NCT07505745: MOTS-c (MDP) study. ↗Official registry record inspected · recruiting, estimated 120 participants, no results posted at review
- Grant et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. 2019. PMID 31572171. ↗Small human exposure study · full-text methods and relevant results reviewed; not efficacy research
- Yu et al. Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy. PMID 40954388; DOI 10.1007/s40256-025-00764-7. ↗Randomized human disease trial · online September 15, 2025, January 2026 issue; primary and nonsignificant clinical-event results retained
- Karaa et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. 2023. PMID 37268435. ↗Randomized phase III trial · full-text primary endpoints and population reviewed; null findings retained
- FDA: Drug Trials Snapshot—Forzinity (elamipretide), approved September 19, 2025. ↗Official approval evidence and indication · randomized versus open-label findings distinguished
- FDA: Forzinity prescribing information. 2025. ↗Official label · indication, accelerated-approval qualification and safety warnings
- Guo et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. 2003. PMID 12732850; DOI 10.1038/nature01627. ↗Cellular and isolated-mitochondria experiments · primary abstract assessed; not demonstrated clinical neuroprotection
- Gidlund et al. Humanin skeletal muscle protein levels increase after resistance training in men with impaired glucose metabolism. 2016. PMID 27923980. ↗Human exercise intervention · indexed abstract assessed; endogenous peptide, not administered Humanin
- ClinicalTrials.gov: Humanin study search. ↗Official registry API records reviewed · seven records, none testing administered Humanin efficacy in this focused search
Prepared by PED Evidence with AI assistance. Independent clinician review has not been completed. Editorial policy · Methodology